Low Dose Naltrexone for Hashimoto’s Thyroiditis:
What the Evidence Shows for Autoimmune Thyroid Conditions in Australia
TL;DR
Low dose naltrexone (LDN) is being used off-label by integrative GPs for Hashimoto’s thyroiditis, the most common autoimmune thyroid condition in Australia. LDN targets the immune dysregulation that drives Hashimoto’s, rather than simply replacing thyroid hormone. Clinical data is still emerging, with a dedicated Australian RCT (ThyroLDN) now registered.
LDN is not TGA approved for this indication. It is prescribed off-label and dispensed by a compounding pharmacy. No treatment outcome guarantees apply.
Low dose naltrexone is gaining attention as an emerging option for Hashimoto’s thyroiditis in Australia. For the estimated 850,000 Australians living with this autoimmune thyroid condition, standard treatment with levothyroxine replaces the thyroid hormone your body can no longer produce adequately. But it does not address the underlying autoimmune process that is progressively destroying the thyroid gland.
Many Hashimoto’s patients continue to experience fatigue, brain fog, weight gain, and mood changes even when their thyroid blood tests appear normal on hormone replacement. This symptom gap has led integrative practitioners to explore therapies that target immune dysfunction directly. LDN is one of the most discussed.
This article explains what Hashimoto’s patients should know about LDN: how it works in autoimmune conditions, what the current evidence shows, and how to access it in Australia.
Why Is LDN Being Used for Autoimmune Conditions?
Direct Answer
LDN modulates the immune system by suppressing overactive inflammatory pathways in the central nervous system. In autoimmune conditions like Hashimoto’s, the immune system mistakenly attacks the body’s own tissues.
LDN’s proposed mechanism, which antagonizes Toll-like receptor 4 (TLR4) and modulates microglial activity, may help reduce this autoimmune inflammatory response without broadly suppressing immune function, unlike immunosuppressant drugs.
Hashimoto’s thyroiditis is driven by autoimmune inflammation. The immune system produces antibodies (anti-TPO and anti-thyroglobulin) that attack thyroid tissue, gradually reducing the gland’s ability to produce thyroid hormones. Levothyroxine replaces the missing hormone but does nothing to slow the autoimmune attack itself.
LDN works through a different pathway. At doses of 1.5 to 4.5mg (far below the 50mg used for addiction medicine), naltrexone appears to reduce the chronic inflammatory signaling that sustains autoimmune activity. Two mechanisms are proposed:
- TLR4 antagonism: LDN blocks Toll-like receptor 4 on immune and glial cells, reducing the production of pro-inflammatory cytokines that drive autoimmune tissue damage.
- Endorphin upregulation: A brief, partial opioid receptor blockade triggers a compensatory increase in endogenous opioids (endorphins), which have immunomodulatory effects that may help rebalance immune function.
This is what makes the LDN conceptually different from standard Hashimoto’s treatment. It targets the autoimmune process rather than the hormonal consequence.
What Does the Evidence Show for LDN and Hashimoto’s?
Direct Answer
Direct clinical trial evidence for LDN specifically in Hashimoto’s thyroiditis is limited but growing. Clinician-reported data suggest reduced thyroid antibody levels and improved symptom scores in a subset of patients. The strongest indirect evidence comes from LDN’s demonstrated anti-inflammatory effects in other autoimmune conditions (Crohn’s disease, MS, fibromyalgia). A dedicated phase 2 Australian RCT (ThyroLDN) has been registered and will provide the first controlled data.
The evidence base for LDN in Hashimoto’s is at an earlier stage than for conditions like fibromyalgia or Crohn’s disease. Here is what is currently available:
Clinician-reported outcomes: Integrative practitioners in the United States, Australia, and the United Kingdom report that a subset of Hashimoto’s patients treated with LDN show measurable reductions in TPO and thyroglobulin antibody levels over 3 to 12 months. Some patients also report improvements in fatigue, brain fog, and overall well-being that go beyond what thyroid hormone optimization alone provides. These are clinical observations, not controlled trial data.
ThyroLDN Trial (ANZCTR: ACTRN12625000131459): A phase 2, double-blind, randomized controlled trial has been registered in Australia. The trial investigates LDN 4.5mg daily for 6 months in Hashimoto’s thyroiditis patients who have residual symptoms despite optimal thyroid hormone replacement. Primary outcome: change in thyroid-specific quality of life. Secondary outcomes include thyroid antibody levels, weight, and symptom scores. This is the first RCT designed specifically for LDN in Hashimoto’s.
LDN in other autoimmune conditions: The strongest controlled evidence for LDN in autoimmune disease comes from Crohn’s disease, where small blinded RCTs (Smith et al.) reported improved symptoms and endoscopic remission. Multiple sclerosis studies have shown quality of life improvements. Meta-analyses in fibromyalgia confirm anti-inflammatory effects. These findings support the biological plausibility of LDN for autoimmune conditions generally, including Hashimoto’s.
What this means in practice: LDN is not a proven or first-line treatment for Hashimoto’s thyroiditis. It does not replace levothyroxine. For patients who remain symptomatic despite optimized thyroid hormone levels, LDN represents a low-cost, low-risk option that targets a different aspect of the disease. The ThyroLDN trial will be the first to provide controlled data.
LDN is not TGA approved for Hashimoto’s thyroiditis or any autoimmune condition. It is prescribed off-label. No guaranteed outcome claims are made. Individual responses vary significantly. Clinical review by Dr. Wesam Abujalala required.
What Do Hashimoto’s Patients Typically Report with LDN?
Based on published clinician observations and patient-reported data (not controlled trials), the most commonly reported effects in Hashimoto’s patients taking LDN include:
- Reduced fatigue: Improved energy levels, particularly the persistent fatigue that does not resolve with thyroid hormone optimization.
- Reduced thyroid antibodies: Some patients show measurable decreases in TPO and thyroglobulin antibody levels over 3 to 12 months.
- Improved brain fog and mood: Better cognitive clarity and reduced mood disturbance.
- Mild early side effects: Vivid dreams and mild sleep disruption in the first 2 to 4 weeks, typically self-resolving.
Not all patients respond. Published response rates for LDN across autoimmune and chronic pain conditions range from 30 to 60 percent, depending on the condition and study. Hashimoto’s-specific response rates have not been established in controlled trials.
Is LDN Safe Alongside Thyroid Medication?
Direct Answer
Yes. LDN does not interact with levothyroxine or liothyronine (T3). It works through a completely different mechanism (immune modulation via TLR4) and does not affect thyroid hormone absorption or metabolism. The key contraindication for LDN is concurrent use of opioid medications. Patients on opioid pain relief must not take LDN.
LDN’s safety profile at 1.5 to 4.5mg daily is well documented across published trials and meta-analyses. No serious adverse events have been attributed to LDN at these doses. The most common early side effects (vivid dreams, mild nausea) are transient. LDN does not cause sedation, weight gain, or cognitive impairment.
How to Access LDN for Hashimoto’s in Australia
Direct Answer
LDN is prescribed off-label by an AHPRA registered GP and dispensed by a compounding pharmacy. No specialist referral is required. At Holistica Health, LDN consultations are available through the Alternative Therapy service via telehealth, nationwide in Australia.
- Complete the pre-screening eligibility check on the Holistica Health website. This takes approximately two minutes.
- Book an Alternative Therapy consultation ($99 initial) with an AHPRA registered GP via telehealth.
- Discuss your Hashimoto’s history, current thyroid medication, symptoms, and whether LDN may be appropriate alongside your existing treatment plan.
- If clinically appropriate, your GP prescribes LDN at a starting dose (typically 1.5mg) with a titration plan. The prescription is sent to a compounding pharmacy for preparation and delivery.
Book Your Alternative Therapy Consultation
Holistica Health offers Alternative Therapy consultations for patients across Australia. No referral required.
Initial consultation: $99. Available Australia-wide via telehealth.
Important: When booking, select ‘Alternative Therapy’ as the service type. LDN consultations are managed under this category.
Complete your pre-screening check: holisticahealth.com.au/Bookyourconsult/pre-screening-checklist/
Frequently Asked Questions
Will LDN replace my thyroid medication?
No. LDN is not a replacement for levothyroxine or any thyroid hormone medication. It targets the autoimmune process, not the hormonal deficiency. If LDN is prescribed, it is used alongside your existing thyroid medication.
How long before I know if LDN is working for my Hashimoto’s?
Most practitioners recommend a 3 to 6 month trial period. Changes in antibody levels may take 3 to 12 months to become measurable. Symptom improvements (energy, brain fog) may be noticed earlier, typically within 4 to 12 weeks.
Is there a clinical trial for LDN and Hashimoto’s?
Yes. The ThyroLDN trial is a phase 2, double-blind RCT registered with the Australian New Zealand Clinical Trials Registry (ACTRN12625000131459). It investigates LDN 4.5mg daily for 6 months in Hashimoto’s patients with residual symptoms despite optimal thyroid hormone replacement.
Can I take LDN if I have Graves’ disease?
LDN has been discussed in the context of both Hashimoto’s and Graves’ disease, but evidence for Graves’ is even more limited. This would need to be assessed individually by your GP. The mechanism (immune modulation) is theoretically relevant to both conditions, but clinical data is insufficient to make general recommendations for Graves’ disease.
Do I book under Integrative Health or Alternative Therapy?
LDN consultations at Holistica Health are booked under the Alternative Therapy service. When completing the pre-screening eligibility check, select ‘Alternative Therapy’ as your service type. The initial consultation is $99.